Publications by authors named "Ludmila S Snegireva"
Article Synopsis
- Uveitis is a common complication in juvenile idiopathic arthritis (JIA) patients, and this study looked into how its presence affects arthritis progression when treated with biologics.
- Researchers compared two groups: those with uveitis (32 patients) and those without (143 patients), using statistical models to analyze joint flare-ups and treatment responses.
- Findings indicated that uveitis increases the risk of arthritis flare-ups, and that using methotrexate alongside biologics may help lower this risk; however, more research is needed for conclusive results.
Objectives: Heart involvement in multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) is a new challenging problem, requiring fast and reliable diagnostics and appropriate treatment. The aim of this study is to describe heart involvement in patients with MIS-C.
Study Design: In this retrospective, multicenter cohort study, data of 122 patients were included.
Unlabelled: JAK-inhibitors are small molecules blocking the JAK-STAT pathway that have proven effective in the treatment of different immune-mediated diseases in adults and juvenile idiopathic arthritis (JIA).
Aim Of Study: To evaluate the safety and efficacy of tofacitinib in children with different rheumatic diseases.
Material And Methods: We extracted information from 24 children with the following diagnosis: JIA ( = 15), undifferentiated systemic autoinflammatory diseases (SAIDs) ( = 7), and juvenile dermatomyositis (JDM) ( = 2) who have been treated with tofacitinib for a period of longer than 6 months.
Distinguishing Between Multisystem Inflammatory Syndrome, Associated With COVID-19 in Children and the Kawasaki Disease: Development of Preliminary Criteria Based on the Data of the Retrospective Multicenter Cohort Study.
Front Pediatr
November 2021
Diagnostic between multisystem inflammatory syndrome associated with COVID-19 in children (MIS-C) and Kawasaki disease (KD) can make difficulties due to many similarities. Our study aimed to create a Kawasaki/MIS-C differentiation score (KMDscore) allowing discrimination of MIS-C and KD. The retrospective multicenter cohort study included clinical, laboratory, and instrumental information about MIS-C ( = 72) and KD ( = 147).
View Article and Find Full Text PDFObjectives: The aim of our study was to evaluate disease courses and outcomes of sJIA children undergoing tocilizumab (TCZ) treatment, and to establish the predictors which distinguish inactive disease and disease flares.
Methods: Our retrospective study included 48 active sJIA children who were refractory to different anti-rheumatic drugs and who were then started on TCZ. The effectiveness of TCZ was assessed by the changes of sJIA attributed signs and symptoms and the remission was judged according to the Wallace (2004) criteria.
Background: Systemic juvenile idiopathic arthritis (SoJIA) is the most striking form of juvenile idiopathic arthritis. The aim of our study was to evaluate the clinical responses and outcomes of children with SoJIA to IL-6 blockade using two different tocilizumab (TCZ) treatment protocols designed for milder and more severe SoJIA patient groups, and evaluate the possibility of achieving biologic-free remission.
Methods: Thirty-seven active SoJIA children who have failed treatment with corticosteroids and other DMARDs were included in our retrospective study.
Objectives: The purpose of our study was to detect early clinical and laboratory signs that help to discriminate macrophage activation syndrome (MAS) from active systemic juvenile idiopathic arthritis (SJIA) without MAS.
Methods: Our retrospective study was based on reviewing the medical charts of the children admitted to the rheumatology department with active SJIA and definite MAS (n = 18) and without MAS (n = 40). We evaluated the data related to SJIA and MAS at the moment of the patient׳s admission.